Judge dismisses Plan B suit
This article was originally published in The Tan Sheet
Executive SummaryA judge in the U.S. District Court for the District of Columbia dismisses a case challenging FDA's OTC approval of Barr Pharmaceuticals' Plan B emergency contraceptive for consumers 18 years of age and older. Judge John Bates ruled March 4 the court "has no jurisdiction" in the case brought by several groups including the Association of American Physicians and Surgeons and Concerned Women for America, in part because they "failed to exhaust their administrative options" before bringing the case to court. The groups unsuccessfully argued that the OTC approval of Plan B put consumers at risk because they did not visit their health care providers, placed pharmacists at increased liability risk and unfairly increased physician competition, among other complaints...
You may also be interested in...
Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.